If you have a loved one or friend who has Alzheimer’s disease you may be interested in a brand-new cutting edge clinical study being conducted by Athira Pharma. Athira is a biopharmaceutical company focused on developing therapies to restore neuronal health and stop neurodegeneration. The company’s goal is to alter the course of neurological diseases and dementias, such as Alzheimer’s, so that patients can regain their memories, lives and family relationships.
For the past several years, we at Answers for Elders have been watching the developments and achievements that are being made to fight the disease. We do believe that a cure is on the horizon, and we’re grateful to organizations like Athira who are making breakthroughs toward that cure! If your friend or loved one meets the criteria, they could benefit from a study of this kind.
On Answers for Elders Radio, we interviewed Dr. Hans Moebius, Chief Medical Officer of Athira Pharma, as he discussed Athira’s innovative regenerative approach to Alzheimer’s disease focused on promoting the body’s natural repair systems.
A key leader in the neurology field for decades, Dr. Moebius discusses the historical landscape of Alzheimer’s disease therapies, and highlights Athira’s innovative and novel approach. This approach has broader therapeutic potential to address multiple dementias, including Parkinson’s disease and many other central nervous system disorders.
Now Enrolling: Athira has two late-stage clinical trials available for Alzheimer’s patients with mild to moderate Alzheimer’s disease in many locations all across the United States and Australia. Those interested in learning more, are encouraged to visit athiraclinicaltrials.com. Related expenses to trial participation are paid for by Athira Pharma and are at no cost to study participants.
The Athira team is motivated and passionate towards making a positive impact on human health. To learn more about the company, visit athira.com.
View Episode Transcript
*The following is the output of transcribing from an audio recording. Although the transcription is largely accurate, in some cases it is incomplete or inaccurate due to inaudible passages or transcription errors.
The following podcast is provided by a Themera Farma and answers for elders radio, and welcome back everyone to answer for elders radio and for those of you that I introduced. That said that, we’re going to have a special guest on this segment. We are very honored to have Dr Hans Mobius, who is the chief medical officer of a Thera Farma, and this is a locally based, amazing organization that has made breakthroughs and Alzheimer’s technology and potentially finding that ultimate cure. and Dr Mobius, I am so excited to have you on our program thank you very much. As on it. Well, we’re excited to have you and you’re calling in from Switzerland, which is amazing. You’re you’re such a global figure and so to have you here on our show we’re very, very honored to do so. And of course I have followed Your Organization for quite some time. A Matter of fact, I’ve even had your staff in for interviews and we worked together with the Alzheimer’s Association and different things like that. So, you know, to have you on our program it’s such an honor and certainly am excited to hear about all the breakthroughs that are happening with Alzheimer’s. So, Dr Marbius, tell us a little bit about you know, just bring our listeners back. Tell us a little bit about Alzheimer’s Disease and what challenges have pharmaceutical companies spaced and finding these kinds of therapies? I’m curious. Yes, thank you for the kind introduction, Susanna. Al Temer’s disease is the most frequent form of the Menia, which may be defined as a gradual but relentless loss memory and function in activities of daily living, which may also lead to behavioral changes challenges over the years. So a temas disease is the sixth leading cause of death in the United States and it is the it’s the only disease in the ten leading causes of death in the United States that cannot be cured, prevented or slowed. There are treatments available that are largely have been have been approved by the FDA twenty years ago, give or take, but everybody knows there’s they leave ample room for improvement, and that is even more sobering since one of ten Americans over the age of sixty five has altemer’s disease. So that make me for more than five million, some say five point eight million Americans in this very moment who are essentially devoid of an effective therapy and ray. Look at that on the background of the life expectancy after a diagnosis, which is usually up to eight years, sometimes ten years. That really gives an impression about the extent of the problem, not only for for those who are suffering, but also for their care givers. Ray, and it’s important to realize that one fourth of Alzheimer’s Care Givers are scent, which Generation Care Givers. They are caring for both someone with a disease and the child or a grandchild. And by often, they often report that the disease ex husts an extraordinary emotional stress on on their role in particular over the time. And so so can I give us our kind, if you will, a secondary victim in their general health status and those who are still working. Many of them had had to quit work. So this is, in a nutshell, I think, the extent, the extent of the problem right. And you know, it’s interesting here in the state of Washington where we’re broadcasting. The state of Washington has a very high degree of you know more than other areas of those afflicted with Alzheimer’s disease, and obviously, I’ve heard close to three Hundredzero of our citizens in the state are right now caring for someone in some capacity as an unpaid family caregiver, and so this is a huge segment of our population and thus the fact that you guys are so proactive and doing things, and I am very interested in you know. I know that. When you know, I was in touch with you guys about three years ago and I have kept a little bit up to speed about the breakthroughs, but of course we had a pandemic and all kinds of things and I’m very interested on you know, a theorist, how do you guys go about addressing this monumental challenge as you do? Yeah, it is. We are not afraid, we are feelings or approach. We are entirely relying on trial participation in order to to show to the FDA, which is the regulatory body who’s approving drugs, that a drug is safe and effective. We are dependent on trial participation and everybody who’s considering that should really think in several ways. It’s about themselves, it’s about their families, but it’s also about future den generations, right. Yes, you’re right. It’s a very complex disease and requires many years of of research before we can even start a clinical trial. So, in case there are this was about a decade and and that is absolutely in keeping with what we what we typically see. So the challenges in the clinical triales are that many approaches are looking to slow the progression of the disease and a Theorra is looking into a more substantial benefit in memory and and daily function and and there is an important innovation that that we are tackling here well, and I am excited to learn a little bit about your clinical trial, but in the midtime I would like to reintroduce you to our listeners. We are speaking with Dr Hans Moby as. He is the chief medical officer of a Theorra farmer and obviously a theory has been working with so many amazing partners, including the University of Washington and many other medical centers here in puget sound, and you guys have an amazing trial coming up and I would love to hear a little bit about how we can help you on the show. Yes, so I thera is currently actively recruiting into two late stage clinical trials, and anybody who would like to know more about these trials can look them up on a Theorra, that is a thh I are a clinical trials in one all in one WorldCom, and there you will not only find information about these trials, but also about the next site that can provide further information and help, should you or your loved one be interested to participate. This is exciting because I know that there’s so many families out there that are looking for answers and this could be you know, having a lot of one being a part of potential breakthroughs is very exciting news for all of us. In contrast to the previous decades, a theory is really focusing to activate a naturally occurring repair mechanism in the brain, and we have utilized certain ways that make us confident that we will be able to to show, also in the clinical trials, that this approach is working. And, Susanna, I would like to add that in these tries, the likelihood to receive active drug is two times higher than the likelihood to receive a place Ebo. We are offering to all the PARTICI participants that are completing the first six months double blind period, that they can participate for another six months in an open label trial. Everybody will receive active drop. Wow, that’s awesome. That’s awesome and certainly, you know, to be, you know, in a community where your organization is locally based is a really powerful thing as well, because you’re really getting a close connection and given that we’re such at the pulse of so many breakthroughs, especially with teaming up at the university Washington, as you guys have, I know, there’s so many opportunities there. So I’m want to just reiterate to our listeners if you go to the website at Hira A, that’s a thera clinical trialscom, and find out, you know, if your loved one or if you know someone that might be interested in participating in this trial, please sign up as soon as possible. I know that isn’t there just a certain number of individuals that you’re going to be accepting into this program? You only have so many thoughts. Is that correct? Yes, that’s correct. Yes, I also want to also wanted to trickly add that, of course, that this is this is coming at no cost to all participants and the companies providing also support for travel costs. Add that is wonderful and certainly important as well. So again, everyone, go to a therah clinical trialscom and find out how to sign up. I it will talk you through it. I went on the website. It was very easy and Dr Mobius, I am so honored again that you are on our show today. We look forward to to talking and helping you know with this study. I think it’ll be exciting. Thank you very much for having me on the program thank you so much for being with us. Take care so to each and every one of you. Have a great week and go to answers for elders. There’s more information on our website about these clinical trials. Let’s get our loved ones that are suffering from Alzheimer’s but the potential of getting some medical breakthrough. So go to answers for elders and until next week, everyone be good to each other. The preceding podcast was provided by a the reformer and answers for elders radio. For more information about the Alzheimer’s clinical trial, go to a thera clinical trialscom.
No post found!
Originally published February 21, 2021